2seventy Reaches End Of The Line As BMS Swoops In To Buy It
The big pharma will spend $286m to acquire the biotech, which restructured in January 2024 to focus exclusively on their shared product, the CAR-T Abecma.
The big pharma will spend $286m to acquire the biotech, which restructured in January 2024 to focus exclusively on their shared product, the CAR-T Abecma.